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0929-6646/Copyright ª 2015, ElsevierBackground/Purpose: BRAF and NRAS mutations have been described in melanomas among
Caucasians and some Asian populations. However, few large-scale studies have investigated
the status and clinical significance of BRAF and NRAS mutations in a Taiwanese population.
Methods: Melanoma samples (nZ 119) were analyzed for mutations in exons 11 and 15 of the
BRAF gene, and in exons 1 and 2 of the NRAS gene. The samples were studied in genomic DNA,
using polymerase chain reaction amplification and Sanger sequencing. Mutations of the BRAF
and NRAS genes were then correlated with clinicopathological features and patients’ prog-
nosis.
Results: The incidence of somatic mutations within the BRAF and NRAS genes was 14.3% (17/
119 patients) and 10.1% (12/119 patients), respectively. Among the 17 patients with BRAF mu-
tations, 15 (88.2%) had V600E mutations. BRAF mutation was frequently detected in younger
patients (pZ 0.0035), in thin melanomas (pZ 0.0181), and in melanomas with less ulceration
(p Z 0.0089). NRAS mutation was more often seen in patients with lymph node metastasis
(pZ 0.0332). Both BRAF and NRASmutations were not significantly correlated with overall sur-
vival and disease-free survival.
Conclusion: As BRAF and NRAS mutations are rare in Taiwan, BRAF- or NRAS-targeted therapies
may be effective only for selected Taiwanese melanoma patients.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.ave no conflicts of interest relevant to this article.
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122 Y.-S. Sheen et al.IntroductionTable 1 BRAF and NRAS mutations identified in 119 pri-
mary melanomas.
Gene Exon Nucleotide
change
Amino acid
change
No. Subtype (n)
BRAF 15 1799T>A V600E 15 ALM (6), SSM (6),
NM (1), LMM (2)
15 1798GT>AA V600K 2 SSM (1), LMM (1)
NRAS 1 G38>A G13D 2 ALM (2)
2 A183>C Q61H 2 ALM (1), NM (1)
2 A182>T Q61L 7 ALM (6), LMM (1)
2 A821>G Q61R 1 ALM (1)
ALM Z acral lentiginous melanoma; LMM Z lentigo maligna
melanoma; NMZ nodular melanoma; SDZ standard deviation;
SSM Z superficial spreading melanoma.Cutaneous melanomas are categorized by the World Health
Organization into the following four subtypes: acral lenti-
ginous melanomas (ALMs), superficial spreading melanomas
(SSMs), lentigo maligna melanomas (LMMs), and nodular
melanomas (NMs).1 BRAF and NRAS are the most frequently
altered oncogenes in cutaneous melanomas. BRAF muta-
tions are detected in approximately 50% and NRAS muta-
tions in approximately 20% of tumors.2 Genetic mutations in
BRAF and NRAS have been correlated to the clinicopatho-
logical features and prognosis of patients with mel-
anomas.1e4 Of note, in a meta-analysis of 36 studies of
different melanoma subtypes, BRAF mutation was
frequently detected in SSMs and in melanomas arising in
nonchronic sun-damaged (non-CSD) skin.2,5 By contrast,
NRAS mutation was frequently evident in NMs and in mel-
anomas arising in skin with chronic sun damage (CSD).2
These observations have been made based mainly on
studies among Caucasian populations. Few similar large
series of studies have been conducted to correlate the
mutation status of BRAF and NRAS to clinicopathological
features of melanoma in Taiwan.
The aim of the current study was to establish the fre-
quency of BRAF and NRAS mutations in a series of mela-
nomas from Taiwanese patients, and to correlate mutation
status with various clinicopathological features and prog-
nosis of these patients.
Materials and methods
Patients and tissues
A total of 119 patients with primary cutaneous melanomas
and nine paired metastases diagnosed at the National
Taiwan University Hospital, Taipei, Taiwan between
January 1995 and November 2009 were enrolled in the
study. All melanoma patients enrolled in the study provided
written informed consent to use their resected tissues. This
study was approved by the Research Ethics Committee of
the National Taiwan University Hospital and was conducted
according to the Declaration of Helsinki principles. The
overall survival (OS) data were collected from chart reviews
and the Taiwan Cancer Registry (follow-up persisted until
December 2013 or until missed follow-up or death of the
patient).
Mutation analysis of BRAF and NRAS genes in
melanoma tissues
DNA was isolated from three consecutive 10-mm sections of
each formalin-fixed, paraffin-embedded tissue sample.
Genomic DNA was extracted using the QIAamp DNA FFPE
Tissue Kit (Qiagen GmbH, Hilden, Germany) according to
the manufacturer’s protocols. DNA concentration was
quantified using an A 260 absorbance with an Eppendorf
BioPhotometer (Eppendorf, Hamburg, Germany). Genomic
DNA (50e100 ng/sample) was used as a template. The iso-
lated DNA was used for real-time LightCycler polymerase
chain reaction (LC PCR), with LightMix kit BRAF V600E(Roche Diagnostics, Indianapolis, IN, USA), a new assay
method for BRAF mutation detection, and methylation-
specific PCR analyses.6 For NRAS mutation detection,
exons 1 and 2 of the NRAS gene were amplified by PCR in at
least two separate preparations of genomic DNA, as
described previously.3
Statistical analysis
The data were summarized using descriptive statistics.
Continuous data, such as age, were described using the
mean  standard deviation of the median (range) for nor-
mally distributed data. Pearson’s Chi-square test was used
to differentiate the rates of different groups. Survival
probabilities were estimated using the KaplaneMeier
method and analyzed by log-rank tests. The influence of
each variable on survival was assessed using a multivariate
Cox proportional hazard model. All statistical tests were
two sided, and p  0.05 was considered statistically sig-
nificant. All statistical analyses were carried out using SAS
9.2 software (SAS Inc., Cary, NC, USA).Results
A total of 119 patients with primary cutaneous melanomas
were recruited for this study. The participants included 66
men and 53 women, with a mean age of 62.1 years (median:
65 years; range: 1e89 years). The most common melanoma
subtypes observed were ALMs (74.8%, 89/119), whereas
NMs (12.6%, 15/119), SSMs (10.1%, 12/119), and LMMs (2.5%,
3/119) were less common. Ulceration was present in 33.6%
of patients. The average thickness of the 119 samples was
3.94 mm, which was much thinner than the previous reports
of samples from Chinese patients.3 One hundred and five
patients (88.2%) were followed for > 5 years or until their
death. The median follow-up duration after diagnosis was
4.4 years (range: 0.1e18.6 years). The 5-year OS rate
among the 119 melanoma patients was 52.5%.
BRAF mutations were found in 17 (14.3%) of the 119
primary cutaneous melanomas (Table 1). The mutation rate
in men was 16.7% and that in women was 11.3%, suggesting
no sex difference in the mutation rates. When mutations
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detected in 58.3% (7/12) of the SSM samples, 6.7% (6/89) of
the ALM samples, 6.7% (1/14) of the NM samples, and 100%
(3/3) of the LMM samples. Of BRAF mutation cases, 15
(88.2%) were found to harbor V600E and two (11.8%) V600K.
In our cohort, patients with BRAF mutation were signifi-
cantly younger than those without BRAF mutations at the
time their melanoma was diagnosed (pZ 0.0035, Table 2).
Patients with BRAF mutation had thinner tumors and less
ulceration at presentation than patients without BRAF
mutation. BRAF mutation was observed in 47.1% of mela-
nomas on non-CSD skin, 37.5% of melanomas on CSD skin,
and 6.4% of ALMs. There were no differences in lymph node
metastasis status and stage of melanoma between the pa-
tients with and without BRAF mutations.
NRASmutations were detected in 12 patients (10.1%). Of
NRAS-mutant cases, seven (58.3%) had Q61L, two (16.7%)
Q61H, two (16.7%) had G13D, and one (8.3%) had Q61R
mutations. NRAS Q61 was the predominant geneticTable 2 Association of BRAF and NRAS mutation status with pa
Clinicopathological factor BRAF genotype, n (%
Mutation Wild type
Age (y)
65 3 (5) 57 (95)
<65 14 (23.7) 45 (76.3)
Sex
Male 11 (16.7) 55 (83.3)
Female 6 (11.3) 47 (88.7)
Thickness (mm)
>4 1 (2.8) 35 (97.2)
4 16 (19.3) 67 (80.7)
Ulceration,
Present 1 (2.5) 39 (97.5)
Absent 16 (20.3) 63 (79.8)
Location
Trunk 2 (33.3) 4 (66.7)
Head and neck 3 (37.5) 5 (62.5)
Extremity 12 (25) 93 (75)
Subtypes
ALM 6 (6.7) 83 (93.3)
SSM 7 (58.3) 5 (41.7)
NM 1 (6.7) 14 (93.3)
LMM 3 (100) 0 (0)
Sun-exposure pattern
CSD 3 (37.5) 5 (62.5)
Non-CSD 8 (47.1) 9 (52.9)
Acral 6 (6.4) 88 (93.6)
Lymph node metastasis
Present 5 (17.9) 23 (82.1)
Absent 12 (13.2) 79 (86.8)
AJCC stage
I 7 (18) 32 (82.1)
II 5 (10.6) 42 (89.4)
III 5 (21.7) 18 (78.3)
IV 0 (0) 10 (100)
Data are presented as n (%).
ALM Z acral lentiginous melanoma; CSD Z melanoma of skin with c
NM Z nodular melanoma; Non-CSDZ melanoma on skin without chroalteration among patients with NRAS mutations (83.3%; 10/
12), which is consistent with previously reported results.7
Age was not significantly different between patients with
and without NRAS mutations (p Z 0.2352). No relationship
was found between sex and NRAS mutations (p Z 0.6881).
The prevalence of > 4 mm thick tumors in NRAS-mutated
melanomas was not significantly different from that in
NRAS wild-type tumors (50% vs. 28%; pZ 0.1813). The rate
of ulceration was not significantly different between NRAS
mutated and NRAS wild-type melanomas (58.3% vs. 30.8%;
p Z 0.1025). NRAS mutations were most frequently found
in LMMs (1/3, 33.3%), followed by in NMs (2/15, 13.3%) and
ALMs (9/89, 10.1%) (Table 2). NRAS mutations were not
detected in SSMs. The difference in the incidence of NRAS
mutations between the subtypes was not statistically sig-
nificant. The incidence of NRAS mutations according to
tumor site was highest in the extremities (11/12, 91.7%),
followed by in the head and neck (1/12, 8.3%). NRAS mu-
tations were not detected in melanomas located on thetients and melanoma characteristics.
) NRAS genotype, n (%)
p Mutation Wild type p
0.0035 0.2352
8 (13.3) 52 (86.7)
4 (6.8) 55 (93.2)
0.4075 0.6881
6 (9.1) 60 (90.9)
6 (11.3) 47 (88.7)
0.0181 0.1813
6 (16.7) 30 (83.3)
6 (7.2) 77 (92.8)
0.0089 0.1025
7 (17.5) 33 (82.5)
5 (6.3) 74 (93.7)
0.0365 1
0 (0) 6 (100)
1 (12.5) 7 (87.5)
11 (10.5) 94 (89.5)
<0.0001 0.2526
9 (10.1) 80 (89.9)
0 (0) 12 (100)
2 (13.3) 13 (86.7)
1 (33.3) 2 (66.7)
<0.0001 1 (12.5) 7 (87.5) 1
1 (5.9) 16 (94.1)
10 (10.6) 84 (89.4)
0.5445 0.0332
6 (21.4) 22 (78.6)
6 (6.6) 85 (93.4)
0.3074 0.0598
1 (2.6) 38 (97.4)
5 (10.6) 42 (89.4)
3 (13) 20 (87)
3 (30) 7 (70)
hronic sun-induced damage; LMM Z lentigo maligna melanoma;
nic sun-induced damage; SSMZ superficial spreading melanoma.
Table 3 Univariate and multivariate analyses of risk factors associated with overall survival.
Clinicopathological factor Univariate risk ratio (95% CI) p Multivariate risk ratio (95% CI) p
Age (65 y) 1.01 (1e1.03) 0.1286
Male sex 2.14 (1.25e3.63) 0.0052 2.00 (1.74e3.41) 0.0107
Thickness (>4 mm) 2.03 (1.32e3.36) 0.0055
Ulceration 1.52 (0.91e2.53) 0.1101
Lymph node metastasis 4.1 (2.43e6.93) <.0001
Stages III, IV 5.42 (3.23e9.09) <.0001 5.22 (3.11e8.76) <0.0001
BRAF mutation 0.69 (0.31e1.51) 0.3464
NRAS mutation 1.67 (0.82e3.39) 0.1564
CI Z confidence interval.
124 Y.-S. Sheen et al.trunk. NRAS-mutated melanomas show a propensity for
developing on the extremities.2,7 The NRAS mutation was
found in 12.5% of CSD melanomas, 10.6% of cases with
ALMs, and 5.88% of cases with non-CSD melanomas (pZ 1).
The lymph node metastasis rate in patients with NRAS
mutations (50.0%) was significant higher (p Z 0.0332) than
that in patients without NRAS mutations (20.6%). These
data suggest that patients harboring NRAS mutations were
prone to having lymph node metastasis.
Two tumors carried mutations in both BRAF exon 15 and
NRAS exon 2 (V600E in BRAF plus Q61H in NRAS of NM on the
calf; V600K in BRAF plus Q61L in NRAS of LMM on the scalp),
which was consistent with the recent reports, but contrary
to the notion that BRAF and NRAS mutations are mutually
exclusive.3,8 One patient was found to have regional nodal
metastasis on presentation and died after 1 year. Another
patient died after 7.7 years.
The BRAF and NRAS genotypes of primary tumors and
metastases were compared in donor-matched paired sam-
ples. All nine paired primary and metastatic melanomas (8
ALMs and 1 NM) were wild-type melanomas in this study.
Overall, the combined frequency of BRAF and NRAS
mutations was 22.7% (27/119), with the highest mutation
frequency being observed within the LMM subgroup (100%,
3/3). In the SSM, ALM, and NM subtypes, the combined
frequencies of BRAF and NRAS mutations were 58.3% (7/
12), 16.9% (15/89), and 13.3% (2/15), respectively.
This cohort included 56 (47.0%) patients who relapsed,
six of whom (6/17; 35.3%) were in the BRAF-mutant group,
nine (9/12; 75%) were in the NRAS-mutant group, and 42
(42/92, 45.7%) had no mutation. Sixty-three patients died:
seven in the BRAF-mutant group (7/17, 41.2%) and nine inTable 4 Univariate and multivariate analyses of risk factors as
Clinicopathological factor Univariate risk ratio (95% CI)
Age (65 y) 1.01 (1e1.03)
Male sex 2.04 (1.26e3.31)
Thickness (>4 mm) 2.05 (1.27e3.36)
Ulceration 1.19 (0.74e1.93)
Lymph node metastasis 4.76 (2.85e7.95)
Stages III, IV 6.17 (3.71e10.25)
BRAF mutation 0.71 (0.35e1.43)
NRAS mutation 1.84 (0.94e3.59)
CI Z confidence interval.the NRAS-mutant group (9/12, 75%), and 49 had no muta-
tion (49/92, 53.3%). As expected, the previously estab-
lished prognostic factors in melanoma, such as male
gender, tumor thickness, lymph node metastasis and stage,
were significantly associated with the OS and disease-free
survival (DFS) in melanomas in the univariate analysis
(Tables 3 and 4). Multivariate Cox regression analysis
showed that male gender and tumor stage were indepen-
dent prognostic factors in OS (Table 3) and DFS (Table 4).
BRAF or NRAS mutations showed no significant association
with OS and DFS in our cohorts (Fig. 1). However, the
number of samples with either mutation is too small to
allow a firm conclusion about survival and mutation status.
Discussion
BRAF and NRAS mutations have been documented in all
subtypes of melanomas.3 However, most studies have been
conducted in Caucasian populations. Thus, there are few
guidelines for deciphering oncogenic differences and
establishing proper treatment of melanomas in Asian pop-
ulations.7e9 In Caucasian populations, the major subtype of
melanoma is SSM on intermittently sun-exposed areas.2 By
contrast, acral melanomas, which constitute a small pro-
portion of melanomas in Caucasians, are the most prevalent
melanoma subtypes in non-Caucasians, especially among
Asians.2,3,9e11 In Taiwan, ALMs comprise between 50% and
58% of cutaneous melanomas.12 However, ALMs accounted
for 74.9% (89/119) of all melanomas in this study. Since the
study consisted of patients who were referred to a single
medical center for treatment and had a relatively small
sample size, it might have the possibility of referral biassociated with disease-free survival.
p Multivariate risk ratio (95% CI) p
0.1591
0.0038 1.77 (1.09e2.89) 0.0213
0.0032
0.4772
<0.0001
<0.0001 5.72 (3.44e9.52) <0.0001
0.34
0.0739
Figure 1 (A) Overall survival of patients according to the presence or absence of BRAF mutation (log-rank test, pZ 0.3433). (B)
Disease-free survival of patients according to the presence or absence of BRAF mutation (log-rank test, p Z 0.3361). (C) Overall
survival of patients according to the presence or absence of NRAS mutation (log-rank test, pZ 0.1518). (D) Disease-free survival of
patients according to the presence or absence of NRAS mutation (log-rank test, p Z 0.0690).
BRAF and NRAS mutations in melanomas in Taiwan 125and not be reflective of Taiwanese population as a whole,
possibly explaining why the frequencies of ALM was higher
than previous report.
BRAF mutations were detected in 14.3% (17/119) of
melanoma in this study, a mutation rate similar to some
previous reports from China, Korea, and Taiwan but lower
than that observed in Japanese and Chinese studies
(Table 5).1,3,9,13e18 This may be due to different sample
sizes, differences in the distribution of melanoma subtypes,Table 5 Summary of BRAF and NRAS mutations in primary
cutaneous melanoma in Asians.
Refs Total
melanomas
BRAF
mutation,
% (n)
NRAS
mutation,
% (n)
Sasaki et al15 35 25.7 (9/35) d
Qi et al14 180 15 (27/180) d
Ashida et al9 79 25.3 (20/79) d
Yamazaki
et al1
79 41.8 (33/79) d
Si et al3 432 25.5 (110/432) 7.2 (31/432)
Zhou et al13 86 16.3 (14/86) 10.5 (9/86)
Jin et al17 202 11.9 (24/202) d
Hong et al16 36 19.4 (7/36) d
Uhara et al7 102 d 7.8 (8/102)
Shen et al18 108 18.5 (20/108) d
Current
study
119 14.3 (17/119) 10.1 (12/119)
Total 1458 20.7 (281/1356) 8.1 (60/739)
d Z not determined.and genetic predisposition.3,9,14,15 The BRAF mutation rate
in Yamazaki et al’s1 study was higher than that in other
studies of Asian melanoma patients, which may be due to
higher proportion of SSMs in their study population (43%). A
number of studies have shown that ALMs have a lower BRAF
mutation frequency than SSMs.1 Recent studies have
revealed that there exist site-specific genetic alterations in
melanoma.2,5,16 In this study, BRAF mutation was more
often seen in the melanomas arising on the head, neck, and
trunk than in those arising on the extremities. BRAF mu-
tations are significantly more common in melanomas
located on the skin with intermittent sun exposure than on
the skin with chronic exposure or with relatively low or no
sun exposure.2,5 We also found that the incidence of BRAF
mutation was lower in CSD and acral melanomas, as
compared with that in non-CSD melanomas. Furthermore,
BRAF mutation was detected in all LMMs (100%, 3/3), which
was in disagreement with a previous study that showed that
melanomas with BRAF mutations occur frequently on non-
CSD skin.2 The rate of NM seems to be lower than that in
a previous report12 and the BRAF mutation rate of NM is
again much lower than that in other studies.1 These dis-
agreements may be due to relatively small sample size, and
these results should be confirmed by future studies using
larger numbers of patients. Bauer et al19 have recently
confirmed that patient age is independently associated
with BRAFmutation frequency.8,10 We can also observe that
BRAF mutation inversely correlated with age, as demon-
strated by the younger age in BRAF-mutation-positive pa-
tients. Some reports have shown that the BRAF mutation is
associated with thinner tumor thickness and a lower rate of
proliferation.2,8,10,16,17 In this study, the proportion of
thickness of > 4 mm was lower in BRAF-mutant melanomas
126 Y.-S. Sheen et al.than that in wild-type tumors. Specifically, the ulceration
rate was higher in melanomas without BRAF mutation in
this study, which may be attributable to a particular
aggressiveness or higher proportion of ALMs with later
diagnosis.20 We could not find any association of BRAF
mutation with lymph node metastasis or stage of mela-
noma. A recent study showed that BRAF mutations were
more frequent in late-stage ALMs than in early-stage ALMs.1
However, there was little difference in the BRAF mutation
frequency between late-stage (8.3%, 2/24) and early-stage
(6.2%, 4/65) ALMs in this study. DFS and OS were not sta-
tistically different among BRAF-mutant and BRAF-wild-type
melanomas in this study, which was comparable to the re-
sults of previous studies.2,8,16,17
The prevalence of NRAS mutations in melanomas of
Taiwanese patients detected in our study was comparable
to that of other East Asian populations (7.2e10.5%, Table
5).3,7 However, the frequency of NRAS mutations was
slightly lower than that of Caucasian patients (15e25%).7
NRAS mutations were detected in 10.1% of ALMs, which
was similar to the frequency reported in the Caucasian
population (10%).8 NRAS mutations were more common in
the melanomas arising in the extremities, which was similar
to the findings of previous reports, suggesting a possible
relationship between NRAS mutations and exogenous skin
stimuli.2,7 Even though statistically insignificant, patients
with NRASmutation had a tendency to have thicker tumors,
a higher ulceration rate, and older age at diagnosis. NRAS
mutation was more frequently observed in melanomas with
CSD.2 However, the frequency of NRAS mutation was not
associated with the sun-exposure pattern in this study. This
result might be explained by the small sample size.
Results of one recent study stated that there was a trend
for patients with NRAS mutation to present with a higher
stage of tumor than patients with wild-type tumors.8 In this
study, patients presenting with late-stage disease also tend
to carry NRAS mutations (p Z 0.0598, Table 2). Further-
more, we noted that NRAS-mutation-positive patients show
a significantly higher lymph node metastasis rate compared
to patients without NRAS mutation (pZ 0.0332, Table 2).21
Oncogenic RAS induces alterations in cellecell and
cellematrix interactions and the acquisition of a migratory
phenotype that ultimately contributes to the metastatic
process.22 In addition, oncogenic RAS protects tumor cells
from matrix-deprivation-induced apoptosis, or anoikis,
thereby contributing to the cells’ capacity to migrate
through the circulatory system.15,22,23 It is interesting to
note, however, that in our study population, survival did
not differ between patients whose primary tumors carried
or did not carry NRAS mutations, even though the mutated
tumors tended to show lymph node metastasis. However,
we observed a trend for NRAS-mutant patients to have
worse DFS than patients with wild-type melanomas. The
statistical power was limited by a low prevalence of pa-
tients with NRAS mutations, and we had few relevant
events for analysis in this study.
Our studies suggest that BRAF as well as NRAS mutations
play a lesser role in the carcinogenesis of malignant mela-
noma in Taiwanese people than in Western patients2 and
that other genetic abnormalities might be involved in the
development of malignant melanoma.14 Furthermore, BRAF
mutation was not associated with lymph node metastasis orstage of melanoma, while NRAS mutation was associated
with higher lymph node metastasis.Acknowledgments
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